| GO ID | GO name | Interaction type | Reference |
|---|---|---|---|
| GO:0001843 | Neural tube closure | Decreases phenotype | PMID:28263823 |
| GO:0001938 | Positive regulation of endothelial cell proliferation | Increases phenotype | PMID:19464254 |
| GO:0002072 | Optic cup morphogenesis involved in camera-type eye development | Decreases phenotype | PMID:28263823 |
| GO:0002523 | Leukocyte migration involved in inflammatory response | Increases phenotype | PMID:34627953 |
| GO:0002639 | Positive regulation of immunoglobulin production | Increases phenotype | PMID:12230500 |
| GO:0004069 | L-aspartate:2-oxoglutarate aminotransferase activity | Increases phenotype | PMID:31168027; PMID:32162908 |
| GO:0006007 | Glucose catabolic process | Decreases phenotype | PMID:26616219 |
| GO:0006171 | Camp biosynthetic process | Affects phenotype | PMID:11886533 |
| GO:0006595 | Polyamine metabolic process | Affects phenotype | PMID:38346634 |
| GO:0006629 | Lipid metabolic process | Affects phenotype | PMID:35156134 |
| GO:0006688 | Glycosphingolipid biosynthetic process | Decreases phenotype | PMID:14662772 |
| GO:0006701 | Progesterone biosynthetic process | Decreases phenotype | PMID:16935330 |
| GO:0006703 | Estrogen biosynthetic process | Increases phenotype | PMID:31352099 |
| GO:0006710 | Androgen catabolic process | Decreases phenotype | PMID:31102695 |
| GO:0006722 | Triterpenoid metabolic process | Decreases phenotype | PMID:32633501 |
| GO:0006749 | Glutathione metabolic process | Affects phenotype | PMID:25851819 |
| GO:0006750 | Glutathione biosynthetic process | Increases phenotype | PMID:25612170; PMID:29407385; PMID:30426164; PMID:31168027 |
| GO:0006754 | Atp biosynthetic process | Decreases phenotype | PMID:23686521; PMID:29407385 |
| GO:0006805 | Xenobiotic metabolic process | Increases phenotype | PMID:10874126; PMID:10874126; PMID:11055268; PMID:11824416; PMID:12237780; PMID:19845430; PMID:11055268; PMID:11091129; PMID:11824416; PMID:12237780; PMID:12695342; PMID:12763371; PMID:19845430; PMID:19903449; PMID:22968811; PMID:24021950; PMID:24382416; PMID:24488374; PMID:27769111; PMID:29162470; PMID:30545405; PMID:34875353; PMID:35101544; PMID:39299374 |
| GO:0006855 | Xenobiotic transmembrane transport | Decreases phenotype | PMID:17174077; PMID:23976943 |
| GO:0006874 | Cellular calcium ion homeostasis | Affects phenotype | PMID:35156134 |
| GO:0006915 | Apoptotic process | Increases phenotype | PMID:12244568; PMID:25612170 |
| GO:0007190 | Activation of adenylate cyclase activity | Affects phenotype | PMID:11886533; PMID:12164941; PMID:12230500 |
| GO:0007204 | Positive regulation of cytosolic calcium ion concentration | Increases phenotype | PMID:23006841 |
| GO:0008202 | Steroid metabolic process | Affects phenotype | PMID:36621641 |
| GO:0008206 | Bile acid metabolic process | Affects phenotype | PMID:36804361 |
| GO:0008207 | C21-steroid hormone metabolic process | Decreases phenotype | PMID:23038793; PMID:26610754 |
| GO:0008209 | Androgen metabolic process | Increases phenotype | PMID:19226368; PMID:19903449; PMID:24323034 |
| GO:0008219 | Cell death | Increases phenotype | PMID:20345925; PMID:24519941; PMID:30262279 |
| GO:0008283 | Cell population proliferation | Decreases phenotype | PMID:12244568; PMID:17432820 |
| GO:0008284 | Positive regulation of cell population proliferation | Affects phenotype | PMID:17966066; PMID:18694951; PMID:20206692; PMID:21566342; PMID:25808816 |
| GO:0008610 | Lipid biosynthetic process | Affects phenotype | PMID:30426164 |
| GO:0008654 | Phospholipid biosynthetic process | Affects phenotype | PMID:30426164 |
| GO:0009060 | Aerobic respiration | Decreases phenotype | PMID:38734219 |
| GO:0009636 | Response to toxic substance | Increases phenotype | PMID:20803752 |
| GO:0010224 | Response to uv-b | Decreases phenotype | PMID:18580964 |
| GO:0010731 | Protein glutathionylation | Increases phenotype | PMID:39793773 |
| GO:0010739 | Positive regulation of protein kinase a signaling | Increases phenotype | PMID:17680988 |
| GO:0010942 | Positive regulation of cell death | Increases phenotype | PMID:14662772; PMID:16330322; PMID:20233841; PMID:22524704; PMID:25512232; PMID:25656284; PMID:25808816; PMID:27836570 |
| GO:0016042 | Lipid catabolic process | Affects phenotype | PMID:34627953; PMID:35358606 |
| GO:0016049 | Cell growth | Decreases phenotype | PMID:25612170; PMID:29407385; PMID:30426164 |
| GO:0016125 | Sterol metabolic process | Decreases phenotype | PMID:12617470; PMID:23125191 |
| GO:0030501 | Positive regulation of bone mineralization | Increases phenotype | PMID:12016462 |
| GO:0030573 | Bile acid catabolic process | Decreases phenotype | PMID:31102695 |
| GO:0030595 | Leukocyte chemotaxis | Decreases phenotype | PMID:2177039 |
| GO:0031394 | Positive regulation of prostaglandin biosynthetic process | Increases phenotype | PMID:12164941 |
| GO:0032308 | Positive regulation of prostaglandin secretion | Increases phenotype | PMID:23688403; PMID:23688403; PMID:24471457; PMID:24471457 |
| GO:0032793 | Positive regulation of creb transcription factor activity | Increases phenotype | PMID:12164941; PMID:17680988 |
| GO:0034199 | Activation of protein kinase a activity | Affects phenotype | PMID:11886533; PMID:12164941; PMID:12230500 |
| GO:0035635 | Entry of bacterium into host cell | Affects phenotype | PMID:12183525 |
| GO:0036378 | Calcitriol biosynthetic process from calciol | Decreases phenotype | PMID:18580964 |
| GO:0042267 | Natural killer cell mediated cytotoxicity | Increases phenotype | PMID:32060585 |
| GO:0042554 | Superoxide anion generation | Affects phenotype | PMID:30426164 |
| GO:0043065 | Positive regulation of apoptotic process | Increases phenotype | PMID:14512701; PMID:15703382; PMID:19587329; PMID:23125191; PMID:24752500; PMID:25787151 |
| GO:0044237 | Cellular metabolic process | Decreases phenotype | PMID:31066974; PMID:35156134; PMID:31103741; PMID:32659470; PMID:34655687; PMID:34762139; PMID:34780725; PMID:36621641 |
| GO:0045333 | Cellular respiration | Decreases phenotype | PMID:23686521 |
| GO:0045669 | Positive regulation of osteoblast differentiation | Increases phenotype | PMID:21542014 |
| GO:0046326 | Positive regulation of glucose import | Decreases phenotype | PMID:26616219 |
| GO:0046466 | Membrane lipid catabolic process | Decreases phenotype | PMID:1884432 |
| GO:0046618 | Xenobiotic export from cell | Decreases phenotype | PMID:26301745 |
| GO:0046649 | Lymphocyte activation | Increases phenotype | PMID:2177039 |
| GO:0048266 | Behavioral response to pain | Decreases phenotype | PMID:17720801 |
| GO:0048295 | Positive regulation of isotype switching to ige isotypes | Increases phenotype | PMID:12230500 |
| GO:0050810 | Regulation of steroid biosynthetic process | Affects phenotype | PMID:26781511 |
| GO:0050965 | Detection of temperature stimulus involved in sensory perception of pain | Decreases phenotype | PMID:17720801 |
| GO:0050966 | Detection of mechanical stimulus involved in sensory perception of pain | Decreases phenotype | PMID:17720801 |
| GO:0051092 | Positive regulation of nf-kappab transcription factor activity | Increases phenotype | PMID:12230500; PMID:16784723; PMID:23688403 |
| GO:0051350 | Negative regulation of lyase activity | Increases phenotype | PMID:31330226 |
| GO:0051354 | Negative regulation of oxidoreductase activity | Increases phenotype | PMID:31330226 |
| GO:0051464 | Positive regulation of cortisol secretion | Decreases phenotype | PMID:20529775 |
| GO:0051881 | Regulation of mitochondrial membrane potential | Affects phenotype | PMID:30426164; PMID:35156134 |
| GO:0052697 | Xenobiotic glucuronidation | Decreases phenotype | PMID:25070100 |
| GO:0055007 | Cardiac muscle cell differentiation | Decreases phenotype | PMID:29337257 |
| GO:0055074 | Calcium ion homeostasis | Affects phenotype | PMID:30426164 |
| GO:0060013 | Righting reflex | Decreases phenotype | PMID:16819505 |
| GO:0060037 | Pharyngeal system development | Decreases phenotype | PMID:28263823 |
| GO:0060081 | Membrane hyperpolarization | Affects phenotype | PMID:35156134 |
| GO:0061154 | Endothelial tube morphogenesis | Increases phenotype | PMID:19464254 |
| GO:0061366 | Behavioral response to chemical pain | Increases phenotype | PMID:23006841 |
| GO:0061370 | Testosterone biosynthetic process | Affects phenotype | PMID:16935330; PMID:31352099 |
| GO:0061436 | Establishment of skin barrier | Decreases phenotype | PMID:18580964 |
| GO:0070265 | Necrotic cell death | Increases phenotype | PMID:23686521; PMID:31629065 |
| GO:0070633 | Transepithelial transport | Decreases phenotype | PMID:18063342 |
| GO:0070640 | Vitamin d3 metabolic process | Decreases phenotype | PMID:12016462; PMID:16824767; PMID:26704532 |
| GO:0070989 | Oxidative demethylation | Affects phenotype | PMID:11055268; PMID:16595712 |
| GO:0070994 | Detection of oxidative stress | Increases phenotype | PMID:24486436 |
| GO:0071466 | Cellular response to xenobiotic stimulus | Decreases phenotype | PMID:23125191 |
| GO:0071486 | Cellular response to high light intensity | Increases phenotype | PMID:24519941 |
| GO:0071493 | Cellular response to uv-b | Affects phenotype | PMID:16365879; PMID:16824767 |
| GO:0071717 | Thromboxane transport | Affects phenotype | PMID:23688403; PMID:24471457 |
| GO:0072593 | Reactive oxygen species metabolic process | Affects phenotype | PMID:35156134 |
| GO:0090030 | Regulation of steroid hormone biosynthetic process | Affects phenotype | PMID:31330226 |
| GO:0097153 | Cysteine-type endopeptidase activity involved in apoptotic process | Increases phenotype | PMID:31629065 |
| GO:0098662 | Inorganic cation transmembrane transport | Decreases phenotype | PMID:12582005 |
| GO:0098739 | Import across plasma membrane | Increases phenotype | PMID:25844889 |
| GO:1901113 | Erythromycin metabolic process | Affects phenotype | PMID:16673044; PMID:16844145 |
| GO:1901216 | Positive regulation of neuron death | Increases phenotype | PMID:19594327 |
| GO:1901661 | Quinone metabolic process | Affects phenotype | PMID:38346634 |
| GO:1901687 | Glutathione derivative biosynthetic process | Affects phenotype | PMID:31168027; PMID:32484342 |
| GO:1902260 | Negative regulation of delayed rectifier potassium channel activity | Increases phenotype | PMID:22975497 |
| GO:1902512 | Positive regulation of apoptotic dna fragmentation | Increases phenotype | PMID:17936189 |
| GO:1903181 | Positive regulation of dopamine biosynthetic process | Decreases phenotype | PMID:19594327 |
| GO:1903409 | Reactive oxygen species biosynthetic process | Affects phenotype | PMID:30426164 |
| GO:1903428 | Positive regulation of reactive oxygen species biosynthetic process | Increases phenotype | PMID:25787151 |
| GO:1903451 | Negative regulation of g1 to g0 transition | Increases phenotype | PMID:20206692 |
| GO:1903609 | Negative regulation of inward rectifier potassium channel activity | Increases phenotype | PMID:22975497 |
| GO:1903761 | Negative regulation of voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization | Increases phenotype | PMID:25822712 |
| GO:1903817 | Negative regulation of voltage-gated potassium channel activity | Increases phenotype | PMID:16542653 |
| GO:1904078 | Positive regulation of estrogen biosynthetic process | Decreases phenotype | PMID:16935330 |
| GO:1904878 | Negative regulation of calcium ion transmembrane transport via high voltage-gated calcium channel | Increases phenotype | PMID:22975497 |
| GO:2000833 | Positive regulation of steroid hormone secretion | Decreases phenotype | PMID:11572034 |
| GO:2000845 | Positive regulation of testosterone secretion | Decreases phenotype | PMID:16684832; PMID:19587329 |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.